Valuation: Sanofi

Market Cap 91.79B 105B 84.65B 78.32B 149B 10,016B 151B 1,014B 397B 4,918B 394B 385B 17,037B P/E 2026 *
11.5x
P/E 2027 * 10.6x
Enterprise Value 101B 116B 93.53B 86.54B 164B 11,067B 167B 1,120B 439B 5,434B 435B 426B 18,824B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.94x
Free-Float
89%
Yield 2026 *
5.56%
Yield 2027 * 5.89%
1 day+0.03%
1 week+0.80%
Current month+1.08%
1 month+1.07%
3 months-6.25%
6 months-7.21%
Current year-7.85%
1 week 73.6
Extreme 73.6
77.25
1 month 71.24
Extreme 71.24
78.23
Current year 70.92
Extreme 70.9227
84.93
1 year 70.92
Extreme 70.9227
93.5
3 years 70.92
Extreme 70.9227
110.84
5 years 70.92
Extreme 70.9227
110.84
10 years 62.99
Extreme 62.99
110.84
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.80% - - 105B
+0.09%+0.25%+54.65%+169.19% 1,085B
-1.63%-1.50%+65.79%+62.70% 624B
-1.12%-4.27%+31.10%+84.44% 442B
+0.88%-0.44%+28.94%+27.84% 332B
-1.40%-8.80%+24.07%+29.51% 277B
+0.44%-2.16%+26.16%+45.91% 282B
+0.16%-1.87%-29.58%-39.57% 217B
-1.19%-2.81%+22.63%+66.30% 196B
-0.72%+2.72%+19.07%+81.19% 167B
Average -0.29%-1.86%+26.98%+58.61% 402.44B
Weighted average by Cap. -0.22%-1.06%+38.36%+85.14%

Financials

2026 *2027 *
Net sales 47.2B 53.95B 43.52B 40.27B 76.43B 5,150B 77.71B 521B 204B 2,529B 203B 198B 8,760B 50.27B 57.46B 46.35B 42.89B 81.4B 5,485B 82.77B 555B 218B 2,693B 216B 211B 9,329B
Net income 7.99B 9.13B 7.37B 6.82B 12.94B 872B 13.16B 88.24B 34.59B 428B 34.29B 33.55B 1,483B 8.9B 10.18B 8.21B 7.6B 14.42B 971B 14.66B 98.32B 38.54B 477B 38.21B 37.38B 1,652B
Net Debt 9.63B 11.01B 8.88B 8.22B 15.6B 1,051B 15.86B 106B 41.7B 516B 41.33B 40.44B 1,788B 5.52B 6.31B 5.09B 4.71B 8.94B 602B 9.09B 60.95B 23.89B 296B 23.69B 23.17B 1,024B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
26-07-10 76.41 -0.03% 0
26-07-09 €74.90 -0.52% 128,266
26-07-08 €75.29 +0.66% 1,114,147
26-07-07 €74.80 +0.39% 592,582
26-07-06 €74.51 -1.71% 4,416,522
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
76.48EUR
Average target price
96.31EUR
Spread / Average Target
+25.93%

Quarterly revenue - Rate of surprise